Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results >2,000 patients in 41 countries, with focus on older patients.
Rachel H. Giles(Dutch Cancer Society), Michael A.S. Jewett(Princess Margaret Cancer Centre), Robert Bick(Kidney Foundation of Canada), Eric Jonasch(The University of Texas MD Anderson Cancer Center), Juan Carlos Julián Mauro(Asociación Española Contra el Cáncer), Lorenzo Marconi(Hospitais da Universidade de Coimbra), Robin Martinez(Patients First), Axel Bex(The Royal Free Hospital), Karin Kastrati, James Larkin(Trinity College Dublin), Sara MacLennan(University of Aberdeen), Carlos Castro, Daniel Yick Chin Heng(University of Calgary), Deborah Maskens(University of Guelph)
Cited by 1
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k